Tekmira closes enrollment in TKM-Ebola trial

Tekmira Pharmaceuticals Corp. recently closed enrollment for the Phase II clinical trial of its TKM-Ebola-Guinea vaccine candidate, saying increased enrollment would not be needed to determine overall therapeutic benefit of the drug.

The vaccine candidate is currently being evaluated for efficacy against the Ebola virus in patients in Sierra Leone. A research team representing the University of Oxford and the International Severe Acute Respiratory and Emergency Infection Coalition (ISARIC) is conducting the study.

"It is a great tribute to the team in Sierra Leone that the trial has been run so efficiently and that we now have substantial experience on the use of TKM-Ebola-Guinea in patients with Ebola,"  Dr. Peter Horby, chief investigator and associate professor of infectious diseases and global health at the University of Oxford, said. "While the trial has reached a statistical endpoint, final conclusions on the efficacy and tolerability of the drug must await full analysis of the data."
The current outbreak of the Ebola virus has been ongoing since December 2013. It has heavily impacted Sierra Leone, Guinea and Liberia. The World Health Organization reports that there have been 15,205 lab-confirmed cases and 27,734 suspected cases as of July 18.

Organizations in this Story

Tekmira Pharmaceuticals Corporation

Want to get notified whenever we write about Tekmira Pharmaceuticals Corporation ?
Next time we write about Tekmira Pharmaceuticals Corporation, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.